Opicapone for motor fluctuations in Parkinson's disease

Affiliations

¹ Department of Medical Pharmacology, University of Lille and Lille University Hospital, Lille, France; INSERM U117, University of Lille and Lille University Hospital, Lille, France; Department of Neurology and Movement Disorders, University of Lille and Lille University Hospital, Lille, France. Electronic address: david.devos@chru-lille.fr.
² INSERM U117, University of Lille and Lille University Hospital, Lille, France; Department of Neurology and Movement Disorders, University of Lille and Lille University Hospital, Lille, France.

Comment

David Devos et al. Lancet Neurol. 2016 Feb.

. 2016 Feb;15(2):127-128.

doi: 10.1016/S1474-4422(15)00346-4. Epub 2015 Dec 23.

¹ Department of Medical Pharmacology, University of Lille and Lille University Hospital, Lille, France; INSERM U117, University of Lille and Lille University Hospital, Lille, France; Department of Neurology and Movement Disorders, University of Lille and Lille University Hospital, Lille, France. Electronic address: david.devos@chru-lille.fr.
² INSERM U117, University of Lille and Lille University Hospital, Lille, France; Department of Neurology and Movement Disorders, University of Lille and Lille University Hospital, Lille, France.

No abstract available

Comment on

Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P; Bi-Park 1 investigators. Ferreira JJ, et al. Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23. Lancet Neurol. 2016. PMID: 26725544 Clinical Trial.